Hepatic embolization through extrahepatic collateral pathways after hepatic arterial embolization for the hepatocellular carcinoma.
Extrahepatic collateral pathways developing after repeated transcatheter arterial embolization (TAE) for hepatocellular carcinoma (HCC) make therapeutic arterial embolization for recurrent lesions extremely difficult. TAE was performed through the collateral pathways using a sophisticated micro-catheter with good trackability and pushability and a coaxial system. Twenty-three TAEs were undertaken through the collateral pathways in 13 patients with recurrent HCC who had extrahepatic collateral pathways after the previous hepatic arterial TAE. There were 69 extrahepatic collateral pathways, with partially obstructed hepatic arteries. On the average, three feeding arteries were seen in the liver. The main extrahepatic collateral pathways were the inferior phrenic artery and epicholedocal artery, 18 vessels and 29 vessels, respectively, accounting for about 80% of the total collateral pathways. TAEs were successful in all cases and the number of embolized vessels was 2.1 on average. The average time of the first collateral TAE after the initial conventional hepatic arterial TAE was 2.3 years. Excellent prognosis was observed with a one-year survival rate of 77% and 3-year survival rate of 38% after the collateral TAE. We consider that collateral TAE for recurrent HCC with obstruction of the hepatic artery is the procedure of choice, is technically feasible, and provides better prognosis for the patients.
Iwata
Y
Y
Department of Radiology I, Tokai University Hospital, Kanagawa, Japan.
Endo
J
J
Saito
T
T
Iwata
T
T
Matsuyama
S
S
Tanaka
Y
Y
Otani
Y
Y
Tsukui
S
S
Goto
K
K
Ikeuchi
S
S
D000328:Adult; D000368:Aged; D000792:Angiography; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D003097:Collateral Circulation; D004621:Embolization, Therapeutic / Q000009:adverse effects; D006499:Hepatic Artery / Q000000981:diagnostic imaging; D006801:Humans; D008102:Liver Circulation; D008113:Liver Neoplasms / Q000628:therapy*; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D019233:Retreatment; D016019:Survival Analysis